Rezatapopt
As of the edition of 20 October 2026, Rezatapopt is a small molecule: in active development; acts on TP53.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 7, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Hormones; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TP53 | Cellular tumor antigen p53 | P04637 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 4 | 2 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| PMV Pharmaceuticals | Lead sponsor of trials | 2020 to now |